Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ascentage Pharma Group International ( (HK:6855) ) has provided an announcement.
Ascentage Pharma Group International announced the further grant of 824,124 Restricted Share Units (RSUs) under its 2021 RSU Scheme to 439 selected employees. This grant represents approximately 0.24% of the company’s total issued share capital and is part of the company’s strategy to incentivize and retain key personnel. The new shares will be issued to a trustee and will rank equally with existing shares. This move is seen as a positive step in aligning employee interests with those of shareholders, potentially enhancing the company’s operational performance and market position.
The most recent analyst rating on (HK:6855) stock is a Buy with a HK$40.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. The company is listed on the Hong Kong Stock Exchange and is actively involved in research and development to provide innovative treatment options in the healthcare sector.
Average Trading Volume: 4,849,537
Technical Sentiment Signal: Buy
Current Market Cap: HK$27.23B
Find detailed analytics on 6855 stock on TipRanks’ Stock Analysis page.